Hypolipidemic activity of 18beta-glycyrrhetinic acid on streptozotocin-induced diabetic rats.
Diabetes mellitus is a significant risk factor for cardiovascular complications. This study was undertaken to investigate the effect of 18beta-glycyrrhetinic acid on plasma glucose and plasma and tissue lipid profiles in streptozotocin-induced diabetic rats. Diabetes was induced in adult male albino rats of the Wistar strain, weighing 180-200 g, by administration of streptozotocin (40 mg/kg of body weight) intraperitoneally. Rats were randomly divided into seven groups. Group I: control animals (normal, nondiabetic animals), Group II: 18beta-glycyrrhetinic acid control, Group III: streptozotocin-diabetic, untreated animals; Groups IV, V and VI: streptozotocin-diabetic animals given 50, 100 and 200 mg 18beta-glycyrrhetinic acid, and Group VII: streptozotocin-diabetic animals given glibenclamide. The levels of total cholesterol, triglycerides, free fatty acids, and phospholipids, were assayed in the plasma besides lipoprotein-cholesterol (high density lipoprotein-cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C) and very low density lipoprotein-cholesterol (VLDL-C)) and tissues (liver, kidney and heart). Total cholesterol, triglyceride, free fatty acid, and phospholipid (LDL-C and VLDL-C in plasma only) levels increased in plasma and tissues significantly, while plasma HDL-cholesterol significantly decreased in diabetic rats. Treatment with 18beta-glycyrrhetinic acid prevented the above changes and improved towards normalcy. Thus administration of 18beta-glycyrrhetinic acid is able to reduce hyperglycemia and hyperlipidemia related to the risk of diabetes mellitus.
Department of Biochemistry and Biotechnology, Faculty of Science, Annamalai University, Annamalainagar-608 002, Tamil Nadu, India.
Panneerselvam
P
Kalaiarasi
Kuppuswamy
K
Kaviarasan
Kodukkur Viswanathan
KV
Pugalendi
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D015243:Cholesterol, VLDL / Q000097:blood; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005230:Fatty Acids, Nonesterified / Q000097:blood; D006034:Glycyrrhetinic Acid / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D006321:Heart / Q000187:drug effects; D006949:Hyperlipidemias / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007668:Kidney / Q000187:drug effects; D050356:Lipid Metabolism / Q000187:drug effects*; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D008099:Liver / Q000187:drug effects; D008297:Male; D015394:Molecular Structure; D010743:Phospholipids / Q000097:blood; D011897:Random Allocation; D051381:Rats; D013311:Streptozocin / Q000494:pharmacology; D014280:Triglycerides / Q000097:blood
D001786:Blood Glucose; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D015243:Cholesterol, VLDL; D005230:Fatty Acids, Nonesterified; D007004:Hypoglycemic Agents; D008055:Lipids; D008074:Lipoproteins; D010743:Phospholipids; D014280:Triglycerides; C119129:18alpha-glycyrrhetinic acid; D013311:Streptozocin; D002784:Cholesterol; D006034:Glycyrrhetinic Acid